Tobacco smoking is considered a major public health challenge, responsible for more than 400,000 deaths each year in the United States alone. To reduce the risk of health damage caused by tobacco smoke (TS) the tobacco industry is marketing and advertising a line of """"""""reduced-exposure"""""""" tobacco products (such as """"""""Advance"""""""" manufactured by Brown &Williamson Tobacco Corporation, """"""""Omni"""""""" and Quest 3 manufactured by Vector Group Ltd), which claim to be less harmful than the leading """"""""light"""""""" cigarette brands. However, the scientific evidence provided is insufficient to evaluate whether these products actually reduce the users'risk for tobacco-related diseases including those associated to vascular impairments. Despite the strong evidence for an association between tobacco smoke and vascular impairment, the impact of TS exposure on the blood-brain barrier (BBB) has been only marginally addressed and studies were limited to only few selective substances among the thousands contained in TS thus, leaving BBB research a substantial understudied area. To address these relevant health public concerns we propose a multimodal approach that involve the parallel use of 1) a novel humanized dynamic in vitro BBB model;2) freshly isolated peripheral blood immune cells (PBMC) and platelets from smoker and non-smoker volunteers;3) 3 vessel occlusion rat models of focal ischemia that will be used to complement the results in vitro and assess the likelihood and magnitude of secondary brain injury (brain edema) caused by TS exposure (from regular and """"""""reduced-exposure"""""""") in synergism with temporary loss of blood flow. Based on these premises we propose to: 1. Evaluate the effect of tobacco smoke from reduced-exposure and regular tobacco products on BBB integrity and function and assess the immunoactivity of each tobacco product. 2. Investigate the effect of TS exposure on BBB function and viability in synergism with rheological changes and how this may impact the pathogenesis of secondary brain injury.

Public Health Relevance

Active and passive tobacco smoking are associated with dysfunction of vascular endothelial physiology in a causative and dose dependent way. Despite the strong evidence for an association between tobacco smoke and vascular impairment, the impact of TS exposure on the blood-brain barrier (BBB) has been only marginally addressed and studies were limited to only few selective substances among the thousands contained in TS thus, leaving BBB research a substantial understudied area. To address these critical issues, we propose to evaluate the effect of tobacco smoke from reduced-exposure and regular tobacco products on BBB integrity and function. We also propose to investigate the effect of TS exposure on BBB function and viability in synergism with rheological changes and how this may impact the pathogenesis of secondary brain injury. This proposal is in response to the PA-09-046. This program announcement specifically asks to explore the differential toxicity of various tobacco and nicotine products. In this respect, we believe that our study will produce a remarkable impact on the awareness of tobacco smoke toxicity in an under considered health area and will provide the foundations for additional studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA029121-05
Application #
8645620
Study Section
Special Emphasis Panel (ZRG1-BDCN-T (02))
Program Officer
Purohit, Vishnudutt
Project Start
2011-03-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
5
Fiscal Year
2014
Total Cost
$297,000
Indirect Cost
$97,000
Name
Texas Tech University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
609980727
City
Lubbock
State
TX
Country
United States
Zip Code
79430
Prasad, Shikha; Sajja, Ravi K; Kaisar, Mohammad A et al. (2016) Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity. Neurotoxicology 56:1-6
Festoff, Barry W; Sajja, Ravi K; van Dreden, Patrick et al. (2016) HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. J Neuroinflammation 13:194
Kaisar, Mohammad A; Sajja, Ravi K; Prasad, Shikha et al. (2016) New experimental models of the blood-brain barrier for CNS drug discovery. Expert Opin Drug Discov :1-15
Kaisar, Mohammad Abul; Prasad, Shikha; Liles, Tylor et al. (2016) A decade of e-cigarettes: Limited research & unresolved safety concerns. Toxicology 365:67-75
Cucullo, Luca; Liles, Taylor (2016) Membrane Transporters and Pharmacological Implications. J Pharmacovigil 4:
Sajja, Ravi K; Rahman, Shafiqur; Cucullo, Luca (2016) Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress. J Cereb Blood Flow Metab 36:539-54
Prasad, Shikha; Cucullo, Luca (2015) Impact of Tobacco Smoking and Type-2 Diabetes Mellitus on Public Health: A Cerebrovascular Perspective. J Pharmacovigil Suppl 2:
Sajja, Ravi K; Cucullo, Luca (2015) Altered glycaemia differentially modulates efflux transporter expression and activity in hCMEC/D3 cell line. Neurosci Lett 598:59-65
Naik, Pooja; Sajja, Ravi K; Prasad, Shikha et al. (2015) Effect of full flavor and denicotinized cigarettes exposure on the brain microvascular endothelium: a microarray-based gene expression study using a human immortalized BBB endothelial cell line. BMC Neurosci 16:38
Naik, Pooja; Cucullo, Luca (2015) Pathobiology of tobacco smoking and neurovascular disorders: untied strings and alternative products. Fluids Barriers CNS 12:25

Showing the most recent 10 out of 25 publications